Literature DB >> 17852826

Biological variation and reference intervals for circulating osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor kappa B ligand and high-sensitivity C-reactive protein.

H P Sennels1, S Jacobsen, T Jensen, M S Hansen, M Ostergaard, H J Nielsen, S Sørensen.   

Abstract

OBJECTIVE: Monitoring inflammatory diseases and osteoclastogenesis with osteopontin (OPN), osteoprotegerin (OPG), total soluble receptor activator of nuclear factor kappa B ligand (total sRANKL) and high-sensitivity C-reactive protein (hsCRP) has recently attracted increased interest. The purpose of our study was to determine reference intervals, variability caused by sampling time, biological variation and stability after repeated freeze-thaw cycles of circulating levels of OPN, OPG, total sRANKL and hsCRP.
MATERIAL AND METHODS: Plasma OPN and plasma OPG concentrations were determined with sandwich ELISA; serum total sRANKL concentration was determined using a two-site sandwich ELISA; and hsCRP was analysed by turbidimetry in 300 Danish blood donors (183 M and 117 F) with a median age of 43 years (range 18-64 years). Variability due to biological variation and sampling time was studied in serial samples from 38 healthy subjects.
RESULTS: The 95th percentiles in the donors were 76 microg/L for OPN, 4.2 pmol/L for OPG, 40.2 nmol/L for total sRANKL and 12 mg/L for hsCRP. The overall medians for both genders were 51 microg/L, 2.2 pmol/L, 0.66 nmol/L and 1.0 mg/L, respectively. We found a significant correlation between hsCRP and OPN (rho = 0.173; p<0.003). The biological within-subject variations were calculated to be 8.2 % for OPN, 8.8% for total sRANKL and 50% for hsCRP.
CONCLUSIONS: Reference intervals have been established with a high analytic performance for OPN and an acceptable analytic performance for OPG and total sRANKL. The study revealed low biological variation for OPN and total sRANKL and high biological variation for hsCRP.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17852826     DOI: 10.1080/00365510701432509

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  11 in total

Review 1.  Banking of biological fluids for studies of disease-associated protein biomarkers.

Authors:  Anne-Sofie Schrohl; Sidse Würtz; Elise Kohn; Rosamonde E Banks; Hans Jørgen Nielsen; Fred C G J Sweep; Nils Brünner
Journal:  Mol Cell Proteomics       Date:  2008-08-01       Impact factor: 5.911

2.  Extracellular Matrix Remodeling Factors as Markers of Carotid Artery Atherosclerosis.

Authors:  Agnieszka Sapa-Wojciechowska; Alina Rak-Pasikowska; Kornel Pormańczuk; Bartłomiej Czapla; Iwona Bil-Lula
Journal:  Cardiol Res Pract       Date:  2020-08-12       Impact factor: 1.866

3.  Short-term bone loss in HIV-infected premenopausal women.

Authors:  Michael T Yin; Dalian Lu; Serge Cremers; Phyllis C Tien; Mardge H Cohen; Qiuhu Shi; Elizabeth Shane; Elizabeth T Golub; Kathryn Anastos
Journal:  J Acquir Immune Defic Syndr       Date:  2010-02       Impact factor: 3.731

Review 4.  Osteoprotegerin in Cardiometabolic Disorders.

Authors:  C Pérez de Ciriza; A Lawrie; N Varo
Journal:  Int J Endocrinol       Date:  2015-05-11       Impact factor: 3.257

5.  Soluble urokinase plasminogen activator receptor as a marker for use of antidepressants.

Authors:  Eva Haastrup; Katrine Grau; Jesper Eugen-Olsen; Christian Thorball; Lars Vedel Kessing; Henrik Ullum
Journal:  PLoS One       Date:  2014-10-20       Impact factor: 3.240

6.  An antibody-free sample pretreatment method for osteopontin combined with MALDI-TOF MS/MS analysis.

Authors:  Yuye Zhou; Joakim Romson; Åsa Emmer
Journal:  PLoS One       Date:  2019-03-07       Impact factor: 3.240

7.  Plasma osteopontin concentrations in patients with cutaneous melanoma.

Authors:  A Filia; F Elliott; T Wind; S Field; J Davies; K Kukalizch; J Randerson-Moor; M Harland; D T Bishop; R E Banks; J A Newton-Bishop
Journal:  Oncol Rep       Date:  2013-08-08       Impact factor: 3.906

8.  Immunomodulation Induced by Stem Cell Mobilization and Harvesting in Healthy Donors: Increased Systemic Osteopontin Levels after Treatment with Granulocyte Colony-Stimulating Factor.

Authors:  Guro Kristin Melve; Elisabeth Ersvaer; Çiğdem Akalın Akkök; Aymen Bushra Ahmed; Einar K Kristoffersen; Tor Hervig; Øystein Bruserud
Journal:  Int J Mol Sci       Date:  2016-07-19       Impact factor: 5.923

9.  Assessment of brain-derived neurotrophic factor and osteopontin in a healthy pediatric population.

Authors:  Joshua D Chew; Larry Markham; Holly M Smith; Yan Ru Su; Kelsey Tomasek; James C Slaughter; Douglas Sawyer; Jonathan H Soslow
Journal:  J Circ Biomark       Date:  2018-10-18

10.  Physical activity and Mediterranean diet as potential modulators of osteoprotegerin and soluble RANKL in gBRCA1/2 mutation carriers: results of the lifestyle intervention pilot study LIBRE-1.

Authors:  Leonie Neirich; Maryam Yahiaoui-Doktor; Jacqueline Lammert; Maryam Basrai; Benjamin Seethaler; Anika Berling-Ernst; Juliane Ramser; Anne S Quante; Thorsten Schmidt; Uwe Niederberger; Kerstin Rhiem; Rita Schmutzler; Christoph Engel; Stephan C Bischoff; Martin Halle; Marion Kiechle; Sabine Grill
Journal:  Breast Cancer Res Treat       Date:  2021-09-27       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.